Tokyo, May 11, 2006 (JCN) - AnGes MG has announced the results of its phase I clinical trials of HGF (Hepatocyte Growth Factor) gene medicine conducted in the US. In the trials, which covered nine serious cases, the company sought the availability of HGF gene medicine in the treatment of ischemic heart disease. The company says that no significant problem was confirmed in terms of initial safety up until three months after administration.
